Connecting biopharmas with the right preclinical cancer models and CRO partners

Cancer Models Forum

Posted by Repositive, July 2020

Preclinical cancer model spotlight: July edition

As part of our commitment to the preclinical oncology community, we want to go one step further to support pharma and biotech researchers during this difficult time. With many scientists around the world returning to the laboratory at reduced capacity or working complex shift patterns, pharma and biotechs need to now plan their preclinical studies more efficiently than ever.

In our new blog series, we’ll be highlighting a selection of popular, interesting and uncommon models available from our specialist CRO partners, which might be of interest for your upcoming studies. And we’re providing insight into the molecular, patient, drug response, histology and growth curve data available for each – information that is currently only available to the enterprise users of our Cancer Models Platform.

1. High-Grade Serous Ovarian Cancer Cell Line

First up in our July model spotlight is this high-grade serous ovarian cancer cell line from one of our specialist CRO partners.

  • Model Information This ovarian cancer cell line was derived from a high-grade ovarian cancer PDX murine model and represents a good in vitro model of the most common and highly heterogeneous ovarian cancer subtype.

  • Drug Treatment Characteristics The patient tumour that this cell line was established from was cisplatin-naïve, meaning that there has been no alteration to the tumour landscape by administration of a chemotherapeutic agent. This not only makes the cell line more representative of the tumour’s heterogeneity in vivo but also makes the cell line particularly effective for studying mechanisms of drug resistance.

  • Physiological relevance This cell line has been used to successfully investigate chemo-induced stemness, metabolic alterations and drug resistance in high-grade serous ovarian cancers, demonstrating its physiological relevance as an in vitro model.

  • Establishment of a rat CDX model In addition to providing a useful in vitro tool, this high-grade serous ovarian cancer cell line has also been shown to establish good CDX models when implanted into a recently developed SCID rat. This high-grade serous ovarian cancer rat CDX model shows a tumour volume growth rate almost 10x higher than a NOD SCID Gamma mouse (NSG) implanted with the same cell line. The faster growth rate usually results in larger samples for downstream analysis and can also reduce the number of passages required, which can lead to loss of tumour heterogeneity in traditional murine PDX models.

Want more information or access to this cell line? Request more information or get in touch with our experts via our Cancer Models Platform.

Learn more CTA button

2. Metastatic Non-Small Cell Lung Cancer PDX model with KRAS mutation

Next, we want to highlight this metastatic non-small cell lung cancer (NSCLC) PDX model.

  • Patient Information The xenograft used to create this PDX model was taken from a patient whose lung cancer had metastasized to the skin.

  • Molecular characteristics This model is characterised by a heterozygous missense mutation in the KRAS gene leading to substitution of glycine to valine at amino acid position 12 in the mature protein. This amino acid substitution has been shown to have a moderate impact.

  • Model drug treatment With 14 single and combination drug treatment responses tested, including Cisplatin, Gemcitabine, Cetuximab and Erlotinib, there is a wealth of data available to help you decide if this model has the required drug response profile. For example, the model shows progression of the disease when treated with a combination of Cisplatin and Gemcitabine, but when given higher doses or there is a change in the treatment schedule, the disease is stabilised. When treated just with Gefitinib, the model shows a partial response; however, treatment with Erlotinib as a single agent leads to progression of the disease.

Want more information or access to this model? Request more information or get in touch with our experts via our Cancer Models Platform.

Learn more CTA button

3. Subcutaneous Melanoma Syngeneic Mouse Model

Finally in this month’s round-up is this subcutaneous melanoma syngeneic mouse model from a specialist CRO based in Europe.

  • Model origin By collecting cells from a spontaneous melanoma that developed behind the ear of a C57BL/6 mouse, this model was created by injecting these cells subcutaneously into right flank of C57BL/6 mice.

  • Growth rate Here’s a graph highlighting the growth rate of the injected melanoma cells as subcutaneous tumours within a C57BL/6 mouse background. Mean ± SEM (n=5; take rate 100%).

Subcutaneous melanoma syngeneic mouse model tumour volume growth rate graph

  • Routes of compound administration This model can be used to administer your compound or therapy via a variety of different routes, including intra-peritoneal, intra-venous, intra-tumoural or subcutaneous injection, as well as by oral administration.

Want more information or access to this model? Request more information or get in touch with our experts via our Cancer Models Platform.

Learn more CTA button

Want to see which models on our Cancer Models Platform match your search criteria?

We have over 6,500 preclinical cancer models from specialist CROs around the globe in our world-leading inventory. See which models have the right molecular phenotype for your study by searching on our Cancer Models Platform.

Get started now CTA button

Image credit: Alinenok sourced from Unsplash

Model data, growth curves and histology images shared with permission from our CRO partners